+----------------------+
| Hero Banner          |
+----------------------+
| ![][image0]          |
+----------------------+
| # About Hyperkalemia |
+----------------------+

---

## Hyperkalemia is an electrolyte disorder<sup>1</sup>

---

### Predisposing factors:<sup>1-5</sup>

+---------------------------------------------------------------------+
| Columns Factors                                                     |
+-------------+-------------+-------------+---------------------------+
| ![][image1] | ![][image2] | ![][image3] | **Concomitant RAASi use** |
|             |             |             |                           |
| **HF**      | **T2D**     | **CKD**     |                           |
+-------------+-------------+-------------+---------------------------+

---

**In studies, the incidence of hyperkalemia over follow-up duration of approximately 1 year was observed to be:6**

---

+----------------------------------------------------------------------------------------------------------------------------------------------------+
| Columns Statistics                                                                                                                                 |
+--------------------------------------------------+-----------------------------------------+-------------------------------------------------------+
| ![Pie chart showing less than 5 percent][image4] | ![Pie chart showing 40 percent][image4] | ![Pie chart showing approximately 73 percent][image4] |
|                                                  |                                         |                                                       |
| **<5%**                                          | **Up to 40%**                           | **\~73%**                                             |
|                                                  |                                         |                                                       |
| with HF                                          | with chronic HF                         | with CKD                                              |
+--------------------------------------------------+-----------------------------------------+-------------------------------------------------------+

---

+---------------------------------------------------------------------------------------------------------------------+
| Columns Callout                                                                                                     |
+---------------------------------------------------------------------------------------------------------------------+
| Diabetes Canada guidelines recommend sodium zirconium cyclosilicate as a treatment option in patients with moderate |
| to high potassium<sup>1</sup>                                                                                       |
+---------------------------------------------------------------------------------------------------------------------+

---

+-----------------------------------------------------------------------------------------------------------------+
| Columns Callout                                                                                                 |
+-----------------------------------------------------------------------------------------------------------------+
| KDIGO guidelines recommend potassium binders as a treatment option for RAASi-induced hyperkalemia<sup>7\*</sup> |
+-----------------------------------------------------------------------------------------------------------------+

---

\* Practice points are consensus-based statements representing the expert judgment of the Work Group and are not graded. Although these statements are developed based on a different methodology, they should not be seen as "less important" or a "downgrade" from graded recommendations.<sup>7</sup>

CKD=chronic kidney disease; HF=heart failure; RAASi=Renin-angiotensin-aldosterone system inhibitor; T2D=Type 2 diabetes.

---

## References

1. Tobe SW, et al. Chronic kidney disease in diabetes: A clinical practice guideline. *Can J Diabetes.* 2025;49:73-86.
2. Kovesdy CP. Updates in hyperkalemia: Outcomes and therapeutic strategies. *Rev Endocr Metab Disord.* 2017;18(1):41-47.
3. Michel A, et al. Risk factors for hyperkalemia in a cohort of patients with newly diagnosed heart failure: a nested case-control study in UK general practice. *European Journal of Heart Failure.* 2015;17:205-213.
4. Weir MR, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. *N Engl J Med.* 2015;372:211-221.
5. National Kidney Foundation. Clinical update on hyperkalemia. A chronic risk for CKD patients and a potential barrier to recommended CKD treatment. 2014. https\://www\.kidney.org/sites/default/files/02-10-6785\_HBE\_Hyperkalemia\_Bulletin.pdf Accessed April 11, 2025.
6. McDonagh TA, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J.* 2021 Sep 21;42(36):3599-3726.
7. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int.* 2024;105(4S):S117-S314.

[image0]: https://main--azn-demo--aemysites.aem.page/media_1845280d4f16197be6756006094a10358781baad7.png#width=3840&height=570

[image1]: https://main--azn-demo--aemysites.aem.page/media_165ef3bcc236d5282b833ad1bf82c2252a749a87a.png#width=252&height=252

[image2]: https://main--azn-demo--aemysites.aem.page/media_1d7c1571eed57fae7ac1095a08d34325ca6d111a6.png#width=252&height=252

[image3]: https://main--azn-demo--aemysites.aem.page/media_1c55e3d04cb95624e8f88c19f62cda0fb59fbe43a.png#width=252&height=252

[image4]: about:error
